Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease

European Journal of Gastroenterology and Hepatology

Volumn 8, Issue 5, 1996, Pages 477-483

  O'Brien, Sharon M ^a,c   Campbell, Gordon R ^b   Burke, Anne F ^a   Maguire, Orla C ^a   Rowlands, Brian J ^b   FitzGerald, Muiris X ^a   Hegarty, John E ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Bile acids salts; Cystic fibrosis; Liver disease; Ursodeoxycholic acid

Indexed keywords

BILE ACID; CHENODEOXYCHOLIC ACID; CHOLIC ACID; DEOXYCHOLIC ACID; GLYCINE; URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; ARTICLE; BILE ACID BLOOD LEVEL; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DIET RESTRICTION; FEMALE; HUMAN; LIVER DISEASE; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; BILE ACIDS AND SALTS; CHOLAGOGUES AND CHOLERETICS; CYSTIC FIBROSIS; FEMALE; HUMANS; LIVER DISEASES; MALE; URSODEOXYCHOLIC ACID;

EID: 0029899007     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Kattwinkel J, Taussig LM, Statland BE, Verter JI: The effects of age on alkaline phosphatase and other serologic liver function tests in normal subjects and patients with cystic fibrosis. J Pediatr 1973, 82:234-242.
2. Nagel RA, Westaby D, Javaid A, Kavani J, Meire HB, Lombard MG, et al.: Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet 1989, ii:1422-1425.
3. Park RW, Grand RJ: Gastrointestinal manifestations of cystic fibrosis: a review. Gastroenterology 1981, 81:1143-1161.
4. Andersen D: Cystic Fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child 1938, 56:344-399.
5. Bodian M: Fibrocystic Disease of the Pancreas: a Congenital Disorder of Mucus Production. New York: Grune & Stratton; 1953:104.
6. Oppenheimer EH, Easterly JR: Hepatic changes in young infants with cystic fibrosis: possible relation to focal biliary cirrhosis. J Pediatr 1975, 86:688-689.
7. Colombo C, Setchell KDR, Podda M, Crosignani A, Roda A Curcio L, et al.: Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr 1990, 117:482-489.
8. Cotting J, Lentze MJ, Reichen J: Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut 1990, 31:919-912.
9. O'Brien S, FitzGerald MX, Hegarty JE: A controlled trial of ursodeoxycholic acid treatment in cystic fibrosis-related liver disease. Eur J Gastroenterol Hepatol 1992, 4:857-863.
10. Setchell KDR, Worthington J: A rapid method for the quantitative extraction of bile acids and their conjugates from serum using commercially available reverse-phase octadecylsilane bonded silica cartridges. Clin Chim Acta 1982, 125:135-144.
11. Lam S, Karmen A: Bile acids. In HPLC of Small Molecules, a Practical Approach. Edited by CK Lim. Oxford, Washington DC: IRL Press; 1986:103-116.
12. Campbell GR, Odling-Smee GW, Rowlands BJ: Determination of bile acids and their conjugates in serum by HPLC using immobilized 3a-hydroxysteroid dehydrogenase for detection. Biomed Chrom 1989, 3:75-78.
13. Kamada S, Maeda M, Tsuji A, Umezawa Y, Kurahashi T: Separation and determination of bile acids by high-performance liquid chromatography using immobilised 3 alpha-hydroxysteroid dehydrogenase and an electrochemical detector. J Chromatog 1982, 239:773-783.
14. Ishii D, Murata S, Takeuchi T: Analysis of bile acids by micro high-performance liquid chromatography with post column enzyme reaction and fluorimetric detection. J Chromatog 1983, 282:569-577.
15. Schmuckler D, Ohta M, Kani S, Sato Y, Kitani K: Hepatic injury induced by bile salts: correlation between biochemical and morphological events. Hepatology 1990, 12:1216-1221.
16. Miyai K, Price VM, Fisher MM: Bile acid metabolism in mammals - ultrastructural studies on the intrahepatic cholestasis induced by lithocholic and chenodeoxycholic acid in the rat. Lab Invest 1971, 24:292-298.
17. Drew R, Priestly BG: Choleretic and cholestatic effects of infused bile salts in the rat. Experientia 1979, 35:809-811.
18. Attili AF, Angelico M, Cantafora A, Alvaro D, Capocaccia L: Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids. Med Hypothesis 1986, 19:57-68.
19. Anwer MS, Engelking LR, Nolan K, Sullivan, Zimniak P, Lester R: Hepatotoxic bile acids increase cytosolic calcium activity of isolated rat hepatocytes. Hepatology 1988, 8:887-891.
20. Scholmerich J, Becher MS, Schmidt K, Schubert R, Kremer B, Feldhaus S, et al.: Influence of hydroxylation and conjugation of bile salts on their membrane damaging properties. Studies on isolated hepatocytes and lipid membrane vesicles. Hepatology 1984, 4:661-666.
21. Fischer RL, Anderson DW, Boyer JL: A prospective morphologic evaluation of hepatic toxicity of chenodeoxycholic acid in patients with cholelithiasis: the National Cooperative Gallstone Study. Hepatology 1982, 2:187-201.
22. Stiehl A, Ast E, Czygan P, Frohling W, Kommerall B: Zur Ursache erhohter serumtransaminasen nach behandlung von patienten mit cholesteringallensteinen mit chenodeoxycholsaure. Inn Med 1976, 3:75-80.
23. Crosignani A, Podda M, Battezzati PM, Bertolini E, Zuin M, Watson D, et al.: Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991, 14:1000-1007.
24. Poupon R, Chretien Y, Poupon R, Paumgartner C: Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1993, 17:599-604.
25. Nakagawa M, Colombo C, Setchell KDR: Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after ursodeoxycholic acid administration. Hepatology 1990, 12:322-334
26. Beuers U, Spengler U, Zwiebel FM, Pauletzki J, Fischer S, Paumgartner C: Effect of ursodeoxycholic on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology 1992, 15:603-608.
27. Rudolph G, Endele R, Senn M, Stiehl A: Effect of UDCA on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis. Hepatology 1993, 17:1028-1032.
28. Weber AM, Roy CC, Morin CL, Lasalle R: Malabsorption of bile acids in children with cystic fibrosis. N Engl J Med 1973, 289:1001-1005.
29. Goodchild MC, Murphy GM, Howell AM, Nutter SA, Anderson CA: Aspects of bile acid metabolism in cystic fibrosis. Arch Dis Child 1975, 50:769-777.
30. Setchell KDR, Smethurst P, Giunta AM, Colombo C: Serum bile acid composition in patients with cystic fibrosis. Clin Chim Acta 1985, 151:101-110.
31. Bali A, Stableforth DE, Asquith P: Prolonged small intestinal transit time in cystic fibrosis. BMJ 1983, 287:1011-1013.
32. Robb TA, Davidson CP, Kirubakaran C: Conjugated bile acids in serum and secretions in response to cholecystokinin/secretin stimulation in children with cystic fibrosis. Gut 1985, 26:1246-1256.
33. Fracchia M, Ferraris R, Petralulo M, Secreto P, Dunn T, Galatola G: Effect of ursodeoxycholic acid on the masses of biliary lipids and alkaline phosphatase within the gallbladder in chronic cholestatic liver disease. Eur J Gastroenterol Hepatol 1992, 4:843-848.
34. Dumont M, Uchman S, Erlinger S: Hypercholeresis induced by ursodeoxycholic acid and 7-ketolithocholic acid in the rat: possible role of bicarbonate transport. Gastroenterology 1980, 79:82-87.
35. Lim AG, Ahmed HA, Jazrawi RP, Northfield TC: The effect of ursodeoxycholic acid and chenodeoxycholic acid on human hepatocyte and erythrocyte membranes. Gut 1993, 34:S45.
36. Guldutuna S, Zimer G, Imhof M, Bhatti S, You T, Leuschner U: Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology 1993, 104:1736-1744.
37. Calmus Y, Gane P, Rouger P, Poupon R: Hepatic expression of class I and class II histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990, 11:12-15.
38. Lo SK, Chapman RW, Dooley JS, Fleming KA: Aberrant HLA-DR antigen expression by bile duct epithelium in primary sclerosing cholangitis is down-regulated by UDCA. Gastroenterology 1993, 104:A943.